This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug delivery			
Malarial vaccine based on an adenoviral vector containing a B cell epitope	<p>An adenoviral vector expressing a B cell epitope could increase the immunogenicity of a malaria vaccine. In a mouse model of malaria, immunization with an adenoviral vector containing a B cell epitope of <i>Plasmodium yoelii</i> circumsporozoite (CS) protein increased antibody and T cell responses and reduced parasite burden in the liver and blood compared with the same vector lacking the B cell epitope. Next steps include identifying the single or combination of malaria B cell epitopes that produce the most immunogenicity.</p> <p>Ad35-CS, a recombinant malaria vaccine with a vector based on adenovirus serotype 35 from Crucell N.V., is in Phase I testing for malaria.</p> <p>SciBX 3(36); doi:10.1038/scibx.2010.1107 Published online Sept. 16, 2010</p>	Patent application filed; not available for licensing	<p>Shiratsuchi, T. <i>et al. J. Clin. Invest.</i>; published online Sept. 1, 2010; doi:10.1172/JCI39812</p> <p>Contact: Moriya Tsuji, Aaron Diamond AIDS Research Center, New York, N.Y. e-mail: mtsuji@adarc.org</p>